Free Access
Med Sci (Paris)
Volume 25, Number 12, Décembre 2009
Anticorps monoclonaux en thérapeutique
Page(s) 1039 - 1045
Section I - De la conception à la production
Published online 15 December 2009
  1. Sisson J, Shapiro B, Beierwaltes WH, et al. Treatment of malignant pheochromocytoma with a new radiopharmaceutical. Trans Assoc Am Physicians 1983; 96 : 209–17. [Google Scholar]
  2. Suresh C, Srivastava L. Investigators review potential of antibodies in cancer detection and therapy. J Nucl Med 1987; 28 : 143–7. [Google Scholar]
  3. Buchegger F, Press OW, Delaloye AB, Ketterer N. Radiolabeled and native antibodies and the prospect of cure of follicular lymphoma. Oncologist 2008; 13 : 657–67. [Google Scholar]
  4. Bellet D, Dangles-Marie V. Anticorps humanisés en thérapeutique. Med Sci (Paris) 2005; 21 : 1054–62 [Google Scholar]
  5. DeNardo GL, DeNardo SJ, Balhorn R. Systemic radiotherapy can cure lymphoma : a paradigm for other malignancies ? Cancer Biother Radiopharm 2008; 23 : 383–97. [Google Scholar]
  6. Horning SJ. Natural history of and therapy for the indolent non-Hodgkin’s lymphomas. Semin Oncol 1993; 20 : 75–88. [Google Scholar]
  7. Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non-Hodgkin’s lymphoma. N Engl J Med 2008; 359 : 613–26. [Google Scholar]
  8. Park SI, Press OW. Radioimmunotherapy for treatment of B-cell lymphomas and other hematologic malignancies. Curr Opin Hematol 2007; 14 : 632–8. [Google Scholar]
  9. Zhang MM, Gopal AK. Radioimmunotherapy-based conditioning regimens for stem cell transplantation. Semin Hematol 2008; 45 : 118–25. [Google Scholar]
  10. Chatal JF, Kraeber-Bodéré F, Barbet J. Consolidation radioimmunotherapy of follicular lymphoma : a step towards cure ? Eur J Nucl Med Mol Imaging 2008; 35 : 1236–9. [Google Scholar]
  11. Morschhauser F, Radford J, Van Hoof A, et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008; 26 : 5156–64. [Google Scholar]
  12. Bodet-Milin C, Kraeber-Bodéré F, Dupas B, et al. Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin’s lymphoma by 18F-fluorodeoxyglucose positron emission tomography. Haematologica 2008; 93 : 390–7. [Google Scholar]
  13. Ivanov A, Swann R, Illidge T. New insights into the mechanisms of action of radioimmunotherapy in lymphoma. J Pharm Pharmacol 2008; 60 : 987–98. [Google Scholar]
  14. Wheldon TE. The radiobiological basis of total body irradiation. Br J Radiol 1997; 70 : 1204–7. [Google Scholar]
  15. Sharkey RM, Karacay H, Chang CH, et al. Improved therapy of non-Hodgkin’s lymphoma xenografts using radionuclides pretargeted with a new anti-CD20 bispecific antibody. Leukemia 2005; 19 : 1064–9. [Google Scholar]
  16. Press OW, Corcoran M, Subbiah K, et al. A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts. Blood 2001; 98 : 2535–43. [Google Scholar]
  17. Goldenberg DM, Gaffar SA, Bennett SJ, Beach JL. Experimental radioimmunotherapy of a xenografted human colonic tumor (GW-39) producing carcinoembryonic antigen. Cancer Res 1981; 41 : 4354–60. [Google Scholar]
  18. Sharkey RM, Pykett MJ, Siegel JA, et al. Radioimmunotherapy of the GW-39 human colonic tumor xenograft with 131I-labeled murine monoclonal antibody to carcinoembryonic antigen. Cancer Res 1987; 47 : 5672–7. [Google Scholar]
  19. Buchegger F, Vacca A, Carrel S, et al. Radioimmunotherapy of human colon carcinoma by 131I-labelled monoclonal anti-CEA antibodies in a nude mouse model. Int J Cancer 1988; 41 : 127–34. [Google Scholar]
  20. Sharkey RM, Goldenberg DM. Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J Nucl Med 2005; 46 : S115–27. [Google Scholar]
  21. Hahn O, Stadler W. Sorafenib. Curr Opin Oncol 2006; 18 : 615–21. [Google Scholar]
  22. Brouwers AH, Mulders PF, de Mulder PH, et al. Lack of efficacy of two consecutive treatments of radioimmunotherapy with 131I-cG250 in patients with metastasized clear cell renal cell carcinoma. J Clin Oncol 2005; 23 : 6540–8. [Google Scholar]
  23. Buchegger F, Pfister C, Fournier K, et al. Ablation of human colon carcinoma in nude mice by 131I-labeled monoclonal anti-carcinoembryonic antigen antibody F(ab’)2 fragments. J Clin Invest 1989; 83 : 1449–56. [Google Scholar]
  24. Schlom J, Eggensperger D, Colcher D, et al. Therapeutic advantage of high-affinity anticarcinoma radioimmunoconjugates. Cancer Res 1992; 52 : 1067–72. [Google Scholar]
  25. Nilsson FY, Tolmachev V. Affibody molecules : new protein domains for molecular imaging and targeted tumor therapy. Curr Opin Drug Discov Dev 2007; 10 : 167–75. [Google Scholar]
  26. Muyldermans S. Single domain camel antibodies : current status. J Biotechnol 2001; 74 : 277–302. [Google Scholar]
  27. Goldenberg DM, Sharkey RM, Paganelli G, et al. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol 2006; 24 : 823–34. [Google Scholar]
  28. Chatal JF, Campion L, Kraeber-Bodéré F, et al. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy : a collaborative study with the French Endocrine Tumor Group. J Clin Oncol 2006; 24 : 1705–11. [Google Scholar]
  29. Behr TM, Liersch T, Greiner-Bechert L, et al. Radioimmunotherapy of small-volume disease of metastatic colorectal cancer. Cancer 2002; 94 : 1373–81. [Google Scholar]
  30. Liersch T, Meller J, Bittrich M, et al. Update of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal liver metastases : comparison of outcome to a contemporaneous control group. Ann Surg Oncol 2007; 14 : 2577–90. [Google Scholar]
  31. Ychou M, Azria D, Menkarios C,et al.Adjuvant radioimmunotherapy trial with iodine-131-labeled anti-carcinoembryonic antigen monoclonal antibody F6 F(ab’)2 after resection of liver metastases from colorectal cancer.Clin Cancer Res 2008; 14 : 3487–93. [Google Scholar]
  32. Milowsky MI, Nanus DM, Kostakoglu L,et al. Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol 2004; 22 : 2522–31. [Google Scholar]
  33. Bander NH, Milowsky MI, Nanus DM,et al. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 2005; 23 : 4591–601. [Google Scholar]
  34. Novak-Hofer I, Schubiger PA. Copper-67 as a therapeutic nuclide for radioimmunotherapy. Eur J Nucl Med Mol Imaging 2002; 29 : 821–30 [Google Scholar]
  35. Kotzerke J, Bunjes D, Scheinberg DA. Radioimmunoconjugates in acute leukemia treatment : the future is radiant. Bone Marrow Transplant 2005; 36 : 1021–6. [Google Scholar]
  36. Sievers EL, Appelbaum FR, Spielberger RT,et al. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy : a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood 1999; 93 : 3678–84. [Google Scholar]
  37. Supiot S, Faivre-Chauvet A, Couturier O,et al. Comparison of the biologic effects of MA5 and B-B4 monoclonal antibody labeled with iodine-131 and bismuth-213 on multiple myeloma. Cancer 2002; 94 : 1202–9. [Google Scholar]
  38. Mattes MJ. Radionuclide-antibody conjugates for single-cell cytotoxicity.Cancer 2002; 94 : 1215–23 [Google Scholar]
  39. Jurcic JG, Larson SM, Sgouros G, et al. Targeted alpha particle immunotherapy for myeloid leukemia. Blood 2002; 100 : 1233–9. [Google Scholar]
  40. Zalutsky MR, Reardon DA, Akabani G,et al. Clinical experience with alpha-particle emitting 211At : treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J Nucl Med 2008; 49 : 30–8. [Google Scholar]
  41. Roboz GJ, Bennett JM, Coleman M, et al. Therapy-related myelodysplastic syndrome and acute myeloid leukemia following initial treatment with chemotherapy plus radioimmunotherapy for indolent non-Hodgkin lymphoma. Leuk Res 2007; 31 : 1141–4. [Google Scholar]
  42. Saphire EO, Parren PW, Pantophlet R, et al. Crystal structure of a neutralizing human IGG against HIV-1 : a template for vaccine design. Science 2001; 293 : 1155–9 [Google Scholar]
  43. Barbet J, Peltier P, Bardet S, et al. Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA x anti-DTPA-indium bispecific antibody. J Nucl Med 1998, 39, 1172–8. [Google Scholar]
  44. Flux G, Bardies M, Monsieurs M, et al. The impact of PET and SPECT on dosimetry for targeted radionuclide therapy. Z Med Phys 2006; 16 : 47–59. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.